Skip to main content
TipRanks
Go Ultimate75% OFF

Hightide Therapeutics Inc (2511) Stock Price & Analysis

1 Followers

2511 Stock Chart & Stats

HK$2.70-HK$0.20(-6.90%)
At close: 4:00 PM GMT+8
HK$2.75HK$3HK$3.25HK$3.5Aug 24Sep 7Sep 21Oct 5Oct 20Nov 2Nov 16
Day’s Range
HKD 2.70 - HKD 2.84
52-Week Range
HKD 1.80 - HKD 4.72
Previous Close
HKD 2.90
Volume
N/A
Average Volume (3M)
266.82K
Market Cap
HKD 1.64B
Enterprise Value
HKD 1.17B
Total Cash (Recent Filing)
HKD 326.36M
Total Debt (Recent Filing)
HKD 154.73M
Price to Earnings (P/E)
―
Beta
1.02
Next Earnings
Mar 26, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Improved Balance Sheet

The return to positive equity represents a meaningful balance-sheet repair compared with the earlier period of negative equity and very high debt. This provides a stronger financial base for continued research investment and improves resilience, although ongoing losses still limit the benefit.

Lower Leverage

A materially lower leverage burden can reduce pressure on future cash flows and preserve greater flexibility for funding therapeutic development. This is a durable improvement in financial structure, though its value depends on the company controlling losses and avoiding renewed debt escalation.

Improving Cash Burn

The reduction in free-cash-flow pressure suggests some improvement in cash consumption relative to the prior two years. While the company remains cash-burning, a sustained moderation in burn could extend funding runway and reduce the frequency or scale of external financing required.

Bears Say

No Reported Revenue

Zero reported revenue means the company has not yet demonstrated commercial monetization of its therapeutic development activities. Until meaningful revenue begins, funding and valuation depend heavily on future clinical or product progress rather than an established operating business.

Persistent Losses

Recurring operating and net losses indicate that the business has not reached profitability or demonstrated operating leverage. Continued losses can consume capital, constrain investment choices, and leave earnings highly dependent on eventual commercialization or other future financing.

Ongoing Cash Burn

Persistent negative operating and free cash flow creates an ongoing requirement for external funding while therapeutic development continues. This raises financing risk, particularly if losses persist, because future capital needs may compete with research priorities and increase dependence on funding markets.

Hightide Therapeutics Inc News

2511 FAQ

What was Hightide Therapeutics Inc’s price range in the past 12 months?
Hightide Therapeutics Inc lowest stock price was HK$1.80 and its highest was HK$4.72 in the past 12 months.
What is Hightide Therapeutics Inc’s market cap?
Hightide Therapeutics Inc’s market cap is HK$1.64B.
When is Hightide Therapeutics Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Hightide Therapeutics Inc’s earnings last quarter?
Hightide Therapeutics Inc released its earnings results on Aug 31, 2026. The company reported -HK$0.327 earnings per share for the quarter.
Is Hightide Therapeutics Inc overvalued?
According to Wall Street analysts Hightide Therapeutics Inc’s price is currently Undervalued.
Does Hightide Therapeutics Inc pay dividends?
Hightide Therapeutics Inc does not currently pay dividends.
What is Hightide Therapeutics Inc’s EPS estimate?
Hightide Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hightide Therapeutics Inc have?
Hightide Therapeutics Inc has 670,035,640 shares outstanding.
What happened to Hightide Therapeutics Inc’s price movement after its last earnings report?
Hightide Therapeutics Inc reported an EPS of -HK$0.327 in its last earnings report. Following the earnings report the stock price went up 3.583%.
Which hedge fund is a major shareholder of Hightide Therapeutics Inc?
Currently, no hedge funds are holding shares in HK:2511
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology